Provided by Tiger Fintech (Singapore) Pte. Ltd.

Coherus BioSciences

1.03
-0.0200-1.90%
Post-market: 1.03-0.0001-0.01%19:57 EST
Volume:1.19M
Turnover:1.23M
Market Cap:118.67M
PE:-260.17
High:1.09
Open:1.05
Low:1.01
Close:1.05
Loading ...

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

GlobeNewswire
·
03 Mar

With 59% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns

Simply Wall St.
·
27 Feb

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

GlobeNewswire
·
24 Feb

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Insider Monkey
·
12 Feb

Barclays Keeps Their Buy Rating on Coherus Biosciences (CHRS)

TIPRANKS
·
27 Jan

Coherus BioSciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Jan

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

GlobeNewswire
·
22 Jan

Coherus BioSciences Inc - FY 2024 Preliminary Net Revenues Expected to Be $255M-$260M

THOMSON REUTERS
·
14 Jan

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
08 Jan

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

GlobeNewswire
·
18 Dec 2024

Coherus BioSciences Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Coherus Biosciences price target lowered to $7 from $12 at H.C. Wainwright

TIPRANKS
·
04 Dec 2024

Unusually active option classes on open December 3rd

TIPRANKS
·
03 Dec 2024

Coherus BioSciences Shares up 42% on Deal to Divest Biosimilar of Amgen's Neulasta

THOMSON REUTERS
·
03 Dec 2024

Sector Update: Health Care Stocks Decline Premarket Tuesday

MT Newswires Live
·
03 Dec 2024

Morning Movers: U.S. Steel falls following Trump vow to block Nippon deal

TIPRANKS
·
03 Dec 2024